Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 15, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume |
|---|---|---|---|
| January 11, 2018 | Ordinary Shares (25p each) | £13.3409 | 835 shares |
Transaction Breakdown:
- Mrs V A Whyte (Company Secretary): Acquired 64 shares.
- Mr I W Whyte (PCA of Company Secretary): Acquired 471 shares.
- Mrs D Connor (PCA of President, Global Manufacturing & Supply): Acquired 300 shares.
Material Changes
The filing does not report material changes to the company's financial position or operations. The reported activity consists of routine share acquisitions resulting from the re-investment of dividends paid to shareholders on January 11, 2018.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of share transactions executed on the London Stock Exchange (XLON).
Investor Verification Checklist
- Verify that the share acquisitions were executed via a Dividend Re-investment Plan (DRIP) as stated.
- Confirm the share price of £13.3409 aligns with the market price on January 11, 2018.
- Ensure the total volume of 835 shares matches the sum of individual transactions reported.
- Check subsequent filings for any amendments to these transaction notifications.